Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment
The DOI matches its Crossref record; 61 of the 65 references it cites were found in a registry or an index.
Abstract
Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a deregulated state of proliferation. The retinoblastoma tumor suppressor protein (pRb) governs a key cell-cycle checkpoint that normally prevents G1-phase cells from entering S-phase in the absence of appropriate mitogenic signals. Cancer cells frequently overcome pRb-dependent growth suppression via constitutive phosphorylation and inactivation of pRb function by cyclin-dependent kinase (CDK) 4 or CDK6 partnered with D-type cyclins. Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non-small cell lung cancer. The emerging, positive clinical data obtained to date finally validate the two decades-old hypothesis that the cyclin D-CDK4/6 pathway is a rational target for cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [2]
In the citing paper
“Because CDK4/6 inhibitors induce G1 phase arrest in tumors expressing functional RB, they may well blunt the effects of cytotoxic drugs or ionizing irradiation (IR), which kill cancer cells in S- or M-phase (2).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [2]
Citations
Cites
1 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301 · cited 1×
“Oncogenic activation of the PI3K–mTOR pathway is also capable of stimulating cyclinD1–CDK4/6 activity, due inpart to the increased translation of the cyclinD1mRNA transcript, and to the stabilization of the cyclin D1 protein (49, 50).”
BackgroundRetractedThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
G 1 Events and Regulation of Cell Proliferation
Pardee, A. B. (1989) · Science · doi:10.1126/science.2683075 · Cited by 2,182 · cited 2×
“Predictably, loss of restriction point control over cell proliferation is commonly selected for in evolving cancer cells (3).”
BackgroundFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
The landscape of cancer genes and mutational processes in breast cancer
The Oslo Breast Cancer Consortium (OSBREAC), Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., Nik-Zainal, S., Martin, S., Varela, I., et al. (2012) · Nature · doi:10.1038/nature11017 · Cited by 1,698
The E2F transcription factor is a cellular target for the RB protein
Chellappan, S. P., Hiebert, S., Mudryj, M., Horowitz, J. M., & Nevins, J. R. (1991) · Cell · doi:10.1016/0092-8674(91)90557-f · Cited by 1,412
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cited by
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
“CDK4/6 inhibitors have shown activity in breast cancer, particularly in combination with endocrine therapy (13, 23, 29).”
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-018-0097-z · Cited by 685
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
“One of the major drivers of cyclinD1-CDK4/6 activity in breast cancer cells is hormone mediated activation of the ER 15 .”
Metadata
- Authors
- VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T.
- Affiliations
- Pfizer (United States) (US)
- Venue
- Clinical Cancer Research
- Published
- 2015-06-30
- Volume
- 21
- Issue
- 13
- Pages
- 2905-2910
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2096979580
- Cited by
- 396
- References
- 65
- Citations by year
- 2026: 18 · 2025: 24 · 2024: 47 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 44 · 2019: 48 · 2018: 32 · 2017: 31 · 2016: 19 · 2015: 7
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6 inhibitors, palbociclib, ribociclib, abemaciclib, retinoblastoma protein, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, breast cancer, melanoma, liposarcoma, non-small cell lung cancer, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Signal Transduction, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cyclin D, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0816
- The paper
- VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015). Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0816
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.